Table 1.
Clinical and Genetic Characteristics for Patients According to BMI Difference Between Diagnosis and Allogeneic HSCT (ΔBMI > –2 vs ≤ –2) in AML Patients Receiving Allogeneic HSCT With BMI at Both Timepoints Available (n = 369).
| Characteristics | All Patients, n = 369 | ΔBMI ≤ –2, n = 212 | ΔBMI > –2, n = 157 | P |
|---|---|---|---|---|
| Sex, n (%) | 0.53 | |||
| Male | 194 | 115 (54) | 79 (50) | |
| Female | 175 | 97 (46) | 78 (50) | |
| BMI at diagnosis, n (%) | <0.001 | |||
| < 25 kg/m2 | 142 | 116 (55) | 26 (17) | |
| 25-29.9 kg/m2 | 156 | 76 (36) | 80 (51) | |
| ≥ 30 kg/m2 | 71 | 20 (9) | 51 (32) | |
| Disease origin, n (%) | 0.001 | |||
| Secondary | 139 | 95 (45) | 44 (28) | |
| De novo | 230 | 117 (55) | 113 (72) | |
| Hemoglobin, g/dL | 0.58 | |||
| Median | 8.9 | 8.9 | 8.9 | |
| Range | 3.2-15.7 | 4.5-14.7 | 3.2-15.7 | |
| Platelet count, × 109/L | 0.40 | |||
| Median | 65 | 64 | 65 | |
| Range | 2-501 | 2-517 | 2-501 | |
| WBC, × 109/L | 0.71 | |||
| Median | 5.7 | 5.7 | 5.7 | |
| Range | 0.1-385 | 0.1-385 | 0.5-366 | |
| Blood blasts, % | 0.20 | |||
| Median | 18 | 17 | 20.5 | |
| Range | 0-98 | 0-97 | 0-98 | |
| BM blasts, % | 0.005 | |||
| Median | 50 | 45.6 | 55 | |
| Range | 0-95 | 0-95 | 3-95 | |
| Normal karyotype, n (%) | 0.83 | |||
| Absent | 211 | 121 (58) | 90 (60) | |
| Present | 146 | 86 (42) | 60 (40) | |
| ELN2017 genetic risk group, n (%) | 0.73 | |||
| Favorable | 83 | 44 (25) | 39 (29) | |
| Intermediate | 98 | 57 (33) | 41 (31) | |
| Adverse | 128 | 74 (42) | 54 (40) | |
| Age at HSCT, y | 0.001 | |||
| Median | 61.0 | 58.9 | 62.5 | |
| Range | 16.3-76.8 | 16.3-74.9 | 20.0-76.8 | |
| BMI at HSCT, n (%) | 0.91 | |||
| < 25 kg/m2 | 204 | 115 (54) | 89 (57) | |
| 25-29.9 kg/m2 | 132 | 78 (37) | 54 (34) | |
| ≥ 30 kg/m2 | 33 | 19 (9) | 14 (9) | |
| Time from diagnosis to HSCT, d | 0.93 | |||
| Median | 120 | 118 | 123 | |
| Range | 7-2504 | 7-2248 | 41-2504 | |
| ECOG performance status at HSCT, n (%) | 0.98 | |||
| 0 | 29 | 16 (8) | 13 (8) | |
| 1 | 175 | 99 (48) | 76 (49) | |
| 2 | 133 | 78 (38) | 55 (36) | |
| 3 | 24 | 14 (7) | 10 (6) | |
| HCT-CI score, n (%) | 0.19 | |||
| 0 | 137 | 86 (44) | 51 (37) | |
| 1/2 | 90 | 55 (28) | 35 (26) | |
| ≥ 3 | 105 | 54 (28) | 51 (37) | |
| Conditioning regimens, n (%) | 0.05 | |||
| Nonmyeloablative | 218 | 117 (55) | 101 (64) | |
| Reduced intensity | 57 | 31 (15) | 26 (17) | |
| Myeloablative | 94 | 64 (30) | 30 (19) | |
| Remission status at HSCT, n (%) | 0.99 | |||
| First CR/CRi | 162 | 150 (71) | 112 (71) | |
| Second CR/CRi | 43 | 25 (12) | 18 (11) | |
| No CR/CRi | 64 | 37 (17) | 27 (18) |
AML = acute myeloid leukemia; BM = bone marrow; BMI = body mass index; CR = complete remission; CRi = complete remission with incomplete peripheral recovery; ECOG = Eastern Cooperative Oncology Group; ELN = European LeukemiaNet; HCT-CI = hematopoietic cell transplantation comorbidity index; HSCT = hematopoietic stem cell transplantation; WBC = white blood count.